Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous PCN-101 (R-ketamine) in Treatment-Resistant Depression
2020-005457-25Phase 2Completed
- Sponsor
- Perception Neuroscience
- Start
- May 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of r-ketamine in treatment-resistant depression (TRD) (3 arms), sponsored by Perception Neuroscience. Primary endpoint: Change from baseline in MADRS total score at 24 hours. Started May 2021; status: completed.
02
Drugs
r-ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2020-005457-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005457-25.